Intracerebral hemorrhage (ICH) refers to bleeding within the brain caused by ruptured blood vessels, leading to brain microbleeding (BMB). Symptoms include sudden headache, nausea, weakness, and difficulty speaking or moving. ICH affects approximately 10-15% of all strokes, with around 200,000 cases annually in North America alone. The market for hemorrhagic stroke treatments is valued at $1.3 billion. Current treatments are mainly focused on managing symptoms and stabilizing patients, with limited drugs specifically targeting the bleeding. Drug development in this area is critical for improving outcomes for ICH patients, as more effective therapies to stop or reverse brain bleeding could significantly reduce mortality and disability.
Zebrafish Model: Using established methods to identify effective compounds to rescue bleeding in 3 dpf larvae